Flow Cytometry assay shows that Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat.No. PD1-H82F3) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 1 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat. No. PD1-H82F3) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing anti-PD-1 antibody. The concentration of PD-L1 used is 2 μg/mL. The IC50 is 0.64 μg/mL (Routinely tested).
Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Atezolizumab | MPDL-3280A; RG-7446; RO-5541267; 52CMI0WC3Y (UNII code) ,MPDL3280A,RG7446 | Approved | Genentech | TECENTRIQ | fda | Urothelial cancer | GENENTECH INC | 2016-05-18 | Triple negative breast cancer, Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Urothelial cancer, Unresectable hepatocellular carcinoma | Details |
| Durvalumab | MEDI-4736; 28X28X9-OKV (UNII code) | Approved | MedImmune, Celgene | IMFINZI | fda | Urothelial cancer | ASTRAZENECA UK LTD | 2017-05-01 | Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Urothelial cancer | Details |
| Avelumab | MSB-0010718C; PF-06834635 ,MSB0010718C,PF06834635 | Approved | Merck Serono, Pfizer | BAVENCIO | fda | Merkel cell carcinoma | EMD SERONO INC | 2017-03-23 | Merkel cell carcinoma, Urothelial cancer | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Pd-1-pik | Pd-1-pik | Phase Ⅰ | Huashan Hospital of Fudan University | Glioblastoma multiforme | Details |
| 艾姆地芬 | Phase Ⅰ | Tianjin Chase Sun Pharmaceutical, Chinese Academy of Medical Sciences | Solid tumours | Details | |
| RC-98 | RC-98; RC98 | Phase Ⅰ | Remegen | Solid tumours | Details |
| Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology) | STI-A1014; ZKAB001; STIA-1014 | Phase Ⅲ | Zhaoke Oncology | Osteosarcoma | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase Ⅰ | Jiangsu huaiyu pharmaceutical | Cancer | Details | |
| CA-327 | CA-327; AUPM-327 | Preclinical | Aurigene, Curis | Cancer | Details |
| JS-003 | JS-003,JS003; JS 003 | Phase Ⅰ | Shanghai Junshi Biosciences | Solid tumours | Details |
| BMS-986189 | BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 | Phase Ⅰ | Bristol-Myers Squibb | Sepsis | Details |
| MAX-10181 | MAX-10181 | Phase Ⅰ | Maxinovel Pharmaceuticals | Solid tumours | Details |
| Bintrafusp alfa | GSK-4045154; M-7824; MSB-0011359C | Phase Ⅲ | Merck Serono, GlaxoSmithKline | Biliary cancer | Details |
| Anti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology) | Phase Ⅰ | Marino Biotechnology | Solid tumours, Glioblastoma | Details | |
| CA-170 | CA-170; AUPM-170 | Phase Ⅱ | Aurigene, Curis | Cancer | Details |
| 89Zr-durvalumab | Phase Ⅱ | Radboud University | Head and neck cancer | Details | |
| KN-046 | KN-046 | Phase Ⅲ | Alphamab | Non small cell lung cancer (NSCLC) | Details |
| LY-3434172 | LY-3434172 | Phase Ⅰ | Lilly | Solid tumours | Details |
| LOR-S03 | CDX-527; LOR-A04; LOR-S01; LOR-S03 | Phase Ⅰ | Celldex | Cancer | Details |
| PD-L1 t-haNK cell therapy | Phase Ⅰ | NantKwest | Solid tumours | Details | |
| GNC-038 | GNC-038 | IND Filing | Sichuan Baili Pharmaceutical | Hematological cancer | Details |
| Recombinant humanized PD-L1 single domain antibody Fc fusion protein | KN035；ASC-22；KN-035；ASC22 | Phase Ⅲ | Alphamab, 3D Medicines, Ascletis | Solid tumours, Septic shock, Sepsis, Biliary cancer | Details |
| CX-072 | CX-072 | Phase Ⅱ | CytomX Therapeutics | Solid tumours, Lymphoma | Details |
| SHR-1701 | SHR-1701,SHR1701; SHR 1701 | Phase Ⅱ | Jiangsu Hengrui Medicine | Lymphoma | Details |
| BGB-A333 | BGB-A333,BGBA333 | Phase Ⅱ | BeiGene | Solid tumours | Details |
| KY-1043 | KY-1043 | Preclinical | Kymab | Solid tumours | Details |
| MT-6402 | MT-6402 | Preclinical | Molecular Templates | Solid tumours | Details |
| GR-1405 | GR-1405,GR1405; GR 1405 | Phase Ⅱ | Chongqing Genrix Biopharmaceutical, Genrix (Shanghai) Biopharmaceutical | Nasopharyngeal cancer, Triple negative breast cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Lymphoma | Details |
| Anti PD-L1 monoclonal antibody (Biocad) | BCD-135 | Phase Ⅰ | Biocad | Solid tumours | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Hisun Pharm) | HS-636 | Phase Ⅰ | Hisun Pharm | Cancer | Details |
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase Ⅰ | Hunan Zhaotai Yongren Biotech | Non small cell lung cancer (NSCLC) | Details |
| IBI-322 | IBI-322 | Phase Ⅰ | Innovent Biologics | Cancer | Details |
| Human source and Fc engineered monoclonal antibody (MabSpace) | MSB-2311,MSB2311 | Phase Ⅰ | MabSpace Biosciences | Solid tumours | Details |
| Durvalumab/Osimertinib Mesylate | Phase Ⅲ | MedImmune | Non small cell lung cancer (NSCLC) | Details | |
| IGV-001 | IGV-001 | Phase Ⅰ | Imvax | Glioblastoma | Details |
| FAZ-053 | FAZ-053,FAZ053 | Phase Ⅰ | Novartis, Laekna Therapeutics | Solid tumours | Details |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase Ⅱ | Changhai Hospital of Shanghai | Pancreatic cancer | Details | |
| FS 118 | FS-118 | Phase Ⅰ | F-star, Merck Serono | hematological malignancies, Solid tumours | Details |
| Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) | Phase Ⅰ | Sanjin Pharmaceutical, Adagene | Cancer | Details | |
| ES101 | ES101 | Phase Ⅰ | Inhibrx, Elpiscience | Solid tumours | Details |
| Cosibelimab | CK-301; TG-1501 | Phase Ⅰ | TG Therapeutics | Lymphoma, Cancer | Details |
| BMS-936559 | BMS-936559; MDX-1105 | Phase Ⅲ | Bristol-Myers Squibb | Non small cell lung cancer (NSCLC) | Details |
| SHR-1316 | SHR-1316 | Phase Ⅲ | Jiangsu Hengrui Medicine | Small cell lung cancer (SCLC), Esophagus cancer | Details |
| ND-021 | ND-021; NM21-1480 | Phase Ⅱ | Numab Therapeutics, CStone Pharmaceuticals | Advanced solid tumors | Details |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase Ⅱ | Taizhou Houde Aoke Technology | Cutaneous squamous cell carcinoma (CSCC), Solid tumours | Details |
| IBI318 | IBI-318 | Phase Ⅰ | Innovent Biologics, Lilly | hematological malignancies, Malignancies | Details |
| Lodapolimab | LY-3300054 | Phase Ⅰ | Lilly | Solid tumours | Details |
| CS-17938 | CS17938 | Preclinical | ChipScreen | Immunological disorders, Cancer | Details |
| TQB-2450 | APL-502; CBT-502; TQ-B2450 | Phase Ⅲ | CBT, Chiatai Tianqing (CTTQ) | Triple negative breast cancer, Non small cell lung cancer (NSCLC), Solid tumours, Liver cancer, Hodgkin lymphoma, Head and neck cancer, Biliary cancer | Details |
| MCLA-145 | MCLA-145 | Phase Ⅰ | Incyte, Merus | Solid tumours | Details |
| KL-A167 | A-167; HBM-9167; KL-A167 | Phase Ⅱ | Sichuan Kelunbotai Biopharmaceutical, Harbour BioMed | Solid tumours | Details |
| Y-111 | Y-111 | Preclinical | YZY Bio | Non small cell lung cancer (NSCLC), Melanoma | Details |
| KD-045 (Nanjing KAEDI Biotech) | KD-045 | Phase Ⅰ | Nanjing KAEDI Biotech | Solid tumours | Details |
| IMC-001 | IMC-001; STI-3031; STI-A1015 | Phase Ⅱ | Sorrento Therapeutics, ImmuneOncia Therapeutics | Gastrointestinal cancer | Details |
| Durvalumab/Selumetinib | Phase Ⅰ | AstraZeneca | Solid tumours | Details | |
| Durvalumab/Gefitinib | Phase Ⅱ | MedImmune | Non small cell lung cancer (NSCLC) | Details | |
| 18F-BMS-986192 | BMS-986192-[18F] | Phase Not Specified | Bristol-Myers Squibb | Cancer | Details |
| INBRX-105 | INBRX-105 | Phase Ⅰ | Inhibrx | Solid tumours, Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma | Details |
| Recombinant human anti-PDL1 monoclonal antibody (CStone Pharmaceuticals) | CS-1001; WBP-3155,CS1001 | Phase Ⅲ | CStone Pharmaceuticals | Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Solid tumours, Lymphoma, Gastroesophageal junction adenocarcinoma, Hodgkin lymphoma | Details |
| HLX-20 | HLX-20,HLX20; HLX 20 | Phase Ⅰ | Shanghai Henlius Biotech | Solid tumours | Details |
| REMD-290 | REMD-290 | Preclinical | REMD Biotherapeutics, Buchang Pharma | Cancer | Details |
| CK-301 | CK-301,CK301 | Phase Ⅰ | Dana-Farber Cancer Institute, Checkpoint | Non small cell lung cancer (NSCLC), Renal cell carcinoma, Merkel cell carcinoma, Urothelial cancer, Mesothelioma, Hodgkin lymphoma, Head and neck cancer, Melanoma | Details |
| GEN-1046 | DuoBody-PD-L1x4-1BB; GEN1046; PD-L1x4-1BB | Phase Ⅱ | Genmab, BioNTech | Triple negative breast cancer, Non small cell lung cancer (NSCLC), Endometrial cancer, Urothelial cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Cervical carcinoma | Details |
| c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | Phase Ⅰ | The Second Hospital of Nanjing Medical University | Primary hepatocellular carcinoma | Details |
This web search service is supported by Google Inc.
A-Z
